Our results prove that SFJD + WM exerts a significant therapeutic impact on mild and ordinary COVID-19 cases, as evidenced by the enhanced negative conversion rate of nucleic acid detection, increased cure and total effective rates, increased chest CT improvement rate, shortened nucleic acid negative conversion time, shortened clinical symptom disappearance time (fever, diarrhea, cough, fatigue, pharyngalgia, nasal congestion, and rhinorrhea), as well as improved levels of laboratory outcomes (CRP, IL-6, Lym, and Neu). The gene discussed is IL6; the disease is COVID-19.